Sorafenib-Induced Ferroptosis via SLC7A11 Suppression in Triple-Negative Breast Cancer Cells: A Combined Bioinformatics and In Vitro Experimental Evidence
Keywords:
Breast Cancer, Ferroptosis, SorafenibAbstract
Background: Ferroptosis has emerged as a promising anticancer strategy because many tumors develop resistance to apoptosis-based therapies, whereas ferroptosis eliminates cancer cells through a distinct iron-dependent mechanism characterized by lipid peroxidation. SLC7A11, a key regulator protein of ferroptosis resistance, is frequently dysregulated in tumors. This study evaluated the clinical relevance of SLC7A11 in breast cancer and investigated the ferroptosis-inducing potential of sorafenib. Methods: TCGA datasets were analyzed through UALCAN Platform to assess SLC7A11 expression and prognostic significance in breast cancer (BRCA), cervical squamous cell carcinoma (CESC), and head and neck squamous cell carcinoma (HNSC). Expression across breast cancer subtypes and patient survival were examined. MDA-MB-231 triple-negative breast cancer cells were treated with sorafenib, and changes in morphology, viability, and lipid peroxidation were assessed using microscopy, viability assays, and C11-BODIPY flow cytometry assay. Results: SLC7A11 expression was significantly elevated in BRCA, CESC, and HNSC tumors compared with normal tissues (all p < 0.001). Within breast cancer, expression was highest in the triple-negative subtype and was associated with poorer overall survival (p = 0.0065). Sorafenib significantly reduced MDA-MB-231 cell viability (p = 0.0021) and induced morphological changes consistent with cell damage. C11-BODIPY analysis demonstrated increased lipid peroxidation following sorafenib treatment. Conclusions: Elevated SLC7A11 is associated with aggressive breast cancer and poor prognosis. Sorafenib reduces breast cancer cell viability and promotes lipid peroxidation, supporting ferroptosis induction as a potential anticancer mechanism.
ABSTRAK
Latar Belakang: Ferroptosis menjadi strategi antikanker yang menjanjikan karena banyak tumor resisten terhadap terapi berbasis apoptosis, sementara ferroptosis menargetkan sel kanker melalui mekanisme jalur berbeda yang bergantung pada besi dan ditandai dengan peroksidasi lipid. SLC7A11, protein regulator utama resistensi ferroptosis, sering mengalami peningkatan pada tumor. Penelitian ini mengevaluasi relevansi klinis SLC7A11 pada kanker payudara dan menginvestigasi potensi induksi ferroptosis dengan sorafenib. Metode: Dataset TCGA dianalisis dari UALCAN untuk menilai ekspresi SLC7A11 dan signifikansi prognostiknya pada kanker payudara, kanker sel skuamosa serviks, dan kanker sel skuamosa kepala-leher. Ekspresi antarsubtipe kanker payudara dan kelangsungan hidup pasien turut dievaluasi. Sel MDA-MB-231 diberi perlakuan sorafenib, kemudian dinilai perubahan morfologi, viabilitas, dan peroksidasi lipid menggunakan mikroskop, uji viabilitas, serta flow cytometry C11-BODIPY. Hasil: Ekspresi SLC7A11 secara signifikan lebih tinggi pada tumor (BRCA, CESC, dan HNSC) dibandingkan dengan jaringan normal (p < 0,001). Pada kanker payudara, ekspresi tertinggi ditemukan pada subtipe triple-negative dan berhubungan dengan kelangsungan hidup yang lebih buruk (p = 0,0065). Sorafenib secara signifikan menurunkan viabilitas sel MDA-MB-231 (p = 0,0021) disertai perubahan morfologi yang konsisten dengan kerusakan sel. Analisis C11-BODIPY mengkonfirmasi peningkatan peroksidasi lipid setelah pemberian sorafenib. Kesimpulan: Peningkatan ekspresi SLC7A11 berkaitan dengan kanker payudara yang agresif dan prognosis buruk. Sorafenib terbukti menurunkan viabilitas sel dan memicu peroksidasi lipid, mendukung induksi ferroptosis sebagai mekanisme antikanker yang potensial.
References
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., Weaver, R., Traina, T. A., Dalenc, F., Aftimos, P., Lynce, F., Diab, S., Cortes, J., O'Shaughnessy, J., Rugo, H. S., & ASCENT Clinical Trial Investigators. (2021). Sacituzumab govitecan in metastatic triple-negative breast cancer. New England Journal of Medicine, 384(16), 1529–1541. https://doi.org/10.1056/NEJMoa2028485
Chandrashekar, D. S., Bashel, B., Balasubramanya, S. A. H., Creighton, C. J., Ponce-Rodriguez, I., Chakravarthi, B., & Varambally, S. (2017). UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia, 19(8), 649–658. https://doi.org/10.1016/j.neo.2017.05.002
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., Morrison, B., & Stockwell, B. R. (2012). Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell, 149(5), 1060–1072. https://doi.org/10.1016/j.cell.2012.03.042
Dixon, S. J., Patel, D. N., Welsch, M., Skouta, R., Lee, E. D., Hayano, M., Thomas, A. G., Gleason, C. E., Tatonetti, N. P., Slusher, B. S., & Stockwell, B. R. (2014). Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife, 3, e02523. https://doi.org/10.7554/eLife.02523
Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015). Ferroptosis as a p53-mediated activity during tumour suppression. Nature, 520(7545), 57–62. https://doi.org/10.1038/nature14344
Koppula, P., Zhuang, L., & Gan, B. (2021). Cystine transporter SLC7A11/xCT in cancer: Ferroptosis, nutrient dependency, and cancer therapy. Protein & Cell, 12(8), 599–620. https://doi.org/10.1007/s13238-020-00789-5
Lang, X., Green, M. D., Wang, W., Yu, J., Choi, J. E., Jiang, L., Liao, P., Zhou, J., Zhang, Q., Dow, A., Saripalli, A., Kryczek, I., Wei, S., Szeliga, W., Vatan, L., Stone, G., Georgiou, G., Huang, L., Zou, W., & Liu, Q. (2019). Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discovery, 9(12), 1673–1685. https://doi.org/10.1158/2159-8290.CD-19-0338
Louandre, C., Ezzoukhry, Z., Godin, C., Barbare, J.-C., Mazière, J.-C., Chauffert, B., Galmiche, A., & Saidak, Z. (2013). Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. International Journal of Cancer, 133(7), 1732–1742. https://doi.org/10.1002/ijc.28159
Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., Brown, L. M., Girotti, A. W., Cornish, V. W., Schreiber, S. L., & Stockwell, B. R. (2014). Regulation of ferroptotic cancer cell death by GPX4. Cell, 156(1–2), 317–331. https://doi.org/10.1016/j.cell.2013.12.010
Yang, W. S., & Stockwell, B. R. (2008). Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic RAS-harboring cancer cells. Chemistry & Biology, 15(3), 234–245. https://doi.org/10.1016/j.chembiol.2008.02.010
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Proceedings of Castle

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


